Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design.

Peter V SguignaRehana Z HussainAnnette OkaiKyle M BlackburnLauren TardoMariam MadinawalaJulie KorichLori A LebsonJeffrey KaplanSalter AmberNavid ManouchehriOlaf Stüve

Published in: Therapeutic advances in neurological disorders (2024)

The CLADRINA trial will generate data regarding the safety, efficacy, and immunological impact of the transition from natalizumab to cladribine. As the pace of immunological knowledge of MS continues, insight into disease modifying therapy transition strategies is needed.

Keyphrases

multiple sclerosis
healthcare
study protocol
electronic health record
clinical trial
mass spectrometry
phase iii
ms ms
phase ii
big data
randomized controlled trial
stem cells
machine learning
mesenchymal stem cells
open label
cell therapy
deep learning